
|Videos|September 9, 2021
Should NPDR patients be treated with anti-VEGF agents?
Author(s)OTE Staff Reports
Dr Jennifer Sun explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Advertisement
Dr Jennifer Sun, associate professor of Ophthalmology, Harvard Medical School; chief at the Center for Clinical Eye Research and Trials, Joslin Diabetes Center, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: BRUNELLO 1-year results for remigromig in DME
2
AAO 2026: MCO-010 sustains vision gains in RP through 4 years
3
AAO 2026: DAYBREAK shows tarcocimab and tabirafusp-ted noninferior to aflibercept in wet AMD
4
AAO 2026: New trials target optic neuritis treatment questions
5


















